Dynamics of Soluble Thrombomodulin and Circulating miRNAs in Patients with Atrial Fibrillation Undergoing Radiofrequency Catheter Ablation

Figures

• 

  Figure 1.. Serum levels of soluble thrombomodulin (s-TM) (A), asymmetric dimethylarginine (ADMA) (B), and high-sensitivity C-reactive protein (hs-CRP) (C), and plasma levels of plasminogen activator inhibitor-1(PAI-1) (D) before and 6 months after catheter ablation in patients in the restored sinus rhythm (SR) and recurrent atrial fibrillation (AF) groups. Lines in the middle of the boxes represent the median values. The lower and upper edges of the boxes represent the first and third quartiles, respectively.

• 

  Figure 2.. Serum levels of mature microRNAs (miRNAs) (A) and primary miRNAs (B) before and 6 months after catheter ablation in patients in the restored sinus rhythm (SR) and recurrent atrial fibrillation (AF) groups. Lines in the middle of the boxes represent the median values. The lower and upper edges of the boxes represent the first and third quartiles, respectively.

• 

  Figure 3.. (A) Correlations between the serum levels of mature miR-22 and miR-126 (left), and primary (pri)-miR-22 and pri-miR-126 (right), in 78 patients with atrial fibrillation (AF; r = 0.873, P < .001; r = 0.298, P = .008, respectively). (B) Correlations between the serum levels of mature miR-22 and pri-miR-22 (left), and mature miR126 and pri-miR-126 (right), in 78 patients with AF (r = 0.873, P < .001; r = 0.298, P = .008, respectively).

• 

  Figure 4.. (A) Correlations between the serum levels of miR-22 and soluble thrombomodulin (s-TM; left), and miR-126 and s-TM (right), in 78 patients with atrial fibrillation (AF; r = −0.341, P = .002; r = −0.255, P = .024, respectively). (B) Correlations between the serum levels of miR-22 and asymmetric dimethylarginine (ADMA; left), and miR-126 and ADMA (right), in 78 patients with AF (r = 0.533; P < .001; r = 0.510, P < .001, respectively).

• 

  Figure 5.. (A) Correlations between the serum levels of primary (pri)-miR-126 and soluble thrombomodulin (s-TM; left), and pri-miR-126 and serum high-sensitivity C-reactive protein (hs-CRP; right), in 78 patients with atrial fibrillation (AF; r = −0.320, P = .004; r = 0.299; P = .008, respectively). (B) Correlations between the serum levels of pri-miR-22 and asymmetric dimethylarginine (ADMA; left), and miR-22 and serum hs-CRP (right), in 78 patients with AF (r = −0.245; P = .032; r = 0.229, P = .044, respectively).